Stallergenes presents data confirming efficacy of 12-month course of its allergic rhinitis therapy
Allergy specialist Stallergenes has, for the first time, presented data from a Phase III study confirming the efficacy and safety of a 12-month course of STG320 in allergic rhinitis.
The company gave an update on the global development program of STG320 for the treatment of allergic rhinitis and asthma, which has included 2,000 patients so far. In Japan, a double-blind, placebo-controlled Phase III study was carried out on 968 adult and adolescent patients with or without intermittent asthma, who suffer from allergic rhinitis to house dust mites.
The study allowed the first registration ever of a house dust mite sublingual immunotherapy tablet. Stallergenes also presented data from the European Phase II/III multicenter study showing the carry over effect after one year of treatment followed by a second treatment-free year for the first time.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze